Nanodelivery systems: An efficient and target‐specific approach for drug‐resistant cancers
Cancer Medicine · 2023
DOI: 10.1002/cam4.6502 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2023. Verfasst von Sumel Ashique und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Pandaveswar School of Pharmacy, Pandaveswar, India. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Neoplasms, Antineoplastic Agents, Drug Delivery Systems. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 292 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cancer treatment is still a global health challenge. Nowadays, chemotherapy is widely applied for treating cancer and reducing its burden. However, its application might be in accordance with various adverse effects by exposing the healthy tissues and multidrug resistance (MDR), leading to disease relapse or metastasis. In addition, due to tumor heterogeneity and the varied pharmacokinetic features of prescribed drugs, combination therapy has only shown modestly improved results in MDR malignancies. Nanotechnology has been explored as a potential tool for cancer treatment, due to the efficiency of nanoparticles to function as a vehicle for drug delivery.
Methods
With this viewpoint, functionalized nanosystems have been investigated as a potential strategy to overcome drug resistance.
Results
This approach aims to improve the efficacy of anticancer medicines while decreasing their associated side effects through a range of mechanisms, such as bypassing drug efflux, controlling drug release, and disrupting metabolism. This review discusses the MDR mechanisms contributing to therapeutic failure, the most cutting‐edge approaches used in nanomedicine to create and assess nanocarriers, and designed nanomedicine to counteract MDR with emphasis on recent developments, their potential, and limitations.
Conclusions
Studies have shown that nanoparticle‐mediated drug delivery confers distinct benefits over traditional pharmaceuticals, including improved biocompatibility, stability, permeability, retention effect, and targeting capabilities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, Pandaveswar School of Pharmacy, Pandaveswar, India.
- Guru Ramdas Khalsa Institute of Science and Technology, Pharmacy, Jabalpur, India.
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- Gomal Center of Biochemistry and Biotechnology, Gomal University, Dera Ismail Khan, Pakistan.
- Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, India.
- Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University Madhya Pradesh (AUMP), Gwalior, India.
ORCID-Profile: Farzad Taghizadeh-Hesary
Zitieren
APA
Ashique, S., Garg, A., Hussain, A., Farid, A., Kumar, P., & Taghizadeh-Hesary, F. (2023). Nanodelivery systems: An efficient and target‐specific approach for drug‐resistant cancers. Cancer Medicine. https://doi.org/10.1002/cam4.6502
Vancouver
Ashique S, Garg A, Hussain A, Farid A, Kumar P, Taghizadeh-Hesary F. Nanodelivery systems: An efficient and target‐specific approach for drug‐resistant cancers. Cancer Medicine. 2023. doi:10.1002/cam4.6502
BibTeX
@article{Ashique2023,
author = {Ashique, Sumel and Garg, Ashish and Hussain, Afzal and Farid, Arshad and Kumar, Prashant and Taghizadeh-Hesary, Farzad},
title = {Nanodelivery systems: An efficient and target‐specific approach for drug‐resistant cancers},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6502}
}
EUVIMED